---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-157286"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-05-31T23:59:59+00:00"
generated_at: "2026-06-14T10:41:45.294223+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# TScan Therapeutics appoints Gavin MacBeath as permanent CEO with increased compensation

## Summary
- Gavin MacBeath, Ph.D., appointed CEO and Class I Director effective May 24, 2023; previously acting CEO since March 2023.
- Base salary increased to $565,000 (from $470,000); target bonus raised to 50% of base (from 40%).
- Received stock option award for 1,121,300 shares at $2.49 per share; contingent on stockholder approval of equity plan amendment.
- Board also granted options for 7,403,100 shares aggregate to other recipients, subject to same amendment.
- Company highlights progress in hematologic and solid tumor programs, and collaboration with Amgen for Crohn's disease.

## SEC filing metadata
- accession: 0001193125-23-157286
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-05-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/0001193125-23-157286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/d515205d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-157286
- JSON: https://secwatch.observer/filing/0001193125-23-157286.json
- Plain text: https://secwatch.observer/filing/0001193125-23-157286.txt

## Key facts
- Executive change
  Gavin MacBeath was appointed as Director at TScan Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/0001193125-23-157286-index.htm
- Executive change
  Gavin MacBeath was appointed as Chief Executive Officer at TScan Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312523157286/0001193125-23-157286-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.